Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $32.00 | $6.40/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| — | Feb 2026 | 99.8% | Janoshik Analytical | — | Unverified | View |
| CJN002 | — | 99.0% | Vanguard Laboratory | — |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. CJC-1295 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Moglabs sell CJC-1295?
Yes — Moglabs currently lists CJC-1295 in 1 variant starting at $32.00 ($6.40/mg).
Is Moglabs's CJC-1295 third-party tested?
Yes — Disclosed Labs has indexed 3 Certificates of Analysis for Moglabs's CJC-1295, with the most recent showing 99.8% purity. Moglabs holds an overall trust grade of C (75/100) across all 38 COAs on file.
What is Moglabs's trust grade for CJC-1295?
Moglabs has an overall Disclosed Labs trust grade of C (75/100), computed from 38 COAs across all peptides. The most recent CJC-1295 COA was issued by Janoshik Analytical.
Where is the cheapest CJC-1295?
As of the latest data, Peptide Supply Co. offers CJC-1295 at $3.80/mg — compare with Moglabs's listing at $6.40/mg. See the full CJC-1295 price comparison.
Is CJC-1295 legal to buy?
CJC-1295 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| View |
| CJD002 | — | 99.8% | Vanguard Laboratory | Endotoxin, Sterility, Heavy metals | Unverified1 flag | View |
Disclosed Labs